A cross-sectional survey on the correlation between Aspirin and sarcopenia in patients with type 2 diabetes mellitus
WANG Jiu-xiang1 ZHU Shen-yin1▲ CHENG Qing-feng2
1.Department of Pharmacy, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China;
2.Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400010,China
Objective To investigate the correlation between Aspirin and sarcopenia in patients with type 2 diabetes.Methods A cross-sectional survey was conducted in 939 patients with type 2 diabetes who were admitted to the First Affiliated Hospital of Chongqing Medical University from June 2013 to December 2015.Patients were divided into Aspirin group (504 cases) and non-Aspirin group (435 cases) according to whether they took aspirin or not.The covariates of the patients were matched by the propensity score matching method, and the correlation between Aspirin and sarcopenia was evaluated by univariate Logistic regression.Results Among the 939 patients with type 2 diabetes, 184 patients (19.6%) had sarcopenia.Propensity score matching method was further used to match the covariates of sarcopenia(age, hemoglobin, body mass index, serum uric acid, high-density lipoprotein cholesterol, triglyceride, neutrophil percentage, diabetic foot, diabetic neuropathy), after matching, Aspirin group (503 cases) and non-Aspirin group (307cases).Before and after propensity score matching, the prevalence rate of sarcopenia in Aspirin group was lower than that in non-Aspirin group, and the difference was statistically significant (P＜0.05).Conclusion Aspirin medication is associated with sarcopenia in patients with type 2 diabetes, which indicate that Aspirin may reduce the risk of sarcopenia.Further validation is required by clinical studies.
Morley JE，Malmstrom TK，Rodriguez-Maas L.Frailty，sarcopenia and diabetes[J].J Am Med Dir Assoc，2014，15（12）：853-859.
[6]
Mesinovic J，Zengin A，De Courten B，et al.Sarcopenia and type 2 diabetes mellitus：a bidirectional relationship [J].Diabetes Metab Syndr Obes，2019，12：1057-1072.
[8]
Guerrero N，Bunout D，Hirsch S，et al.Premature loss of muscle mass and function in type 2 diabetes[J].Diabetes Res Clin Pract，2016，117：32-38.
[1]
Cruz-Jentoft AJ，Bahat G，Bauer J，et al.Sarcopenia：revised European consensus on definition and diagnosis[J].J Am Med Dir Assoc，2019，20（8）：1047-1049.
[4]
Kim BJ，Lee SH，Kwak MK，et al.Inverse relationship between serum hsCRP concentration and hand grip strength in older adults：a nationwide population-based study[J].Aging（Albany NY），2018，10（8）：2051-2061.
[5]
David S，Barbora DC，Ebeling PR.Sarcopenia：a potential cause and consequence of type 2 diabetes in Australia′s ageing population?[J].Med J Aust，2016，205（7）：329-333.
[7]
Trierweiler，Heloísa，Kisielewicz G，et al.Sarcopenia：a chronic complication of type 2 diabetes mellitus[J].Diabetol Metab Syndr，2018，10（1）：25.
[9]
Ratchford SM，Lavin KM，Perkins RK，et al.Aspirin as a COX Inhibitor and Anti-inflammatory Drug in Human Skeletal Muscle[J].J Appl Physiol，2017，123（6）:1610-1616.
[10]
Genuth S，Alberti KG，Bennett P，et al.Follow-up report on the diagnosis of diabet es mellitus[J].Diabetes Care，2003，26：3160-3167.
[11]
American Diabetes Association.Standards of medical care in diabetes-2012[J].Diabetes Care，35（Suppl 1）：S11-63.
Wang T，Feng X，Zhou J，et al.Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre sarcopenia in Chinese elderly[J].Sci Rep，2016，6：38 937.
Chul JH.Sarcopenia，frailty，and diabetes in older adults[J].Diabetes Metab J，2016，40（3）：182.
[16]
Landi F，Marzetti E，Liperoti R，et al.Nonsteroidal antiinflammatory drug （NSAID） use and sarcopenia in older people：results from the ilSIRENTE study[J].J Am Med Dir Assoc，2013，14（8）：626.e9-13.
[17]
Legrand D，Adriaensen W，Vaes B，et al.The relationship between grip strength and muscle mass （MM），inflammatory biomarker s and physical performance in community -dwelling very old persons[J].Arch Gerontol Geriatr，2013，57（3）：345-351.
[18]
Trappe TA，Standley RA，Jemiolo B，et al.Prostaglandin and myokine involvement in the cyclooxygenase-inhibiting drug enhancement of skeletal muscle adaptations to resistance exercise in older adults [J].Am J Physiol Regul Integr Comp Physiol，2013，304（3）：R198-205.[A4]
[19]
Trappe TA，Liu SZ.Effects of prostaglandins and COXinhibiting drugs on skeletal muscle adaptations to exercise[J].J Appl Physiol（1985），2013，115（6）：909-919.
[20]
Korotkova M.The skeletal muscle arachidonic acid cascade in health and inflammatory disease[J].Nat Rev Rheumatol，2014，10（5）：295-303.
[21]
Trappe TA，Ratchford SM，Brower BE，et al.Editor's choice：COX inhibitor influence on skeletal muscle fiber size and metabolic adaptations to resistance exercise in older adults[J].J Gerontol A Biol Sci Med Sci，2016，71（10）：1289-1294.
[22]
Elze MC，Gregson J，Baber U，et al.Comparison of propensity score methods and covariate adjustment[J].J Am Coll Cardiol，2017，69（3）：345-357.
京公网安备 11010502046607号